Brought to you by 
Paladin Labs buys ViRexx Medical
30 Dec 2008
Executive Summary
Canadian specialty pharmaco Paladin Labs has acquired all of the outstanding shares of ViRexx Medical (developing therapeutics for infectious diseases and cancer) for $1.25mm up front plus another $2.5mm in potential earn-outs.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Paladin Labs buys ViRexx Medical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice